Marta M. Guerra

Marta M. Guerra

Auto-generated profile, based on publicly available information

Marta M. Guerra

Hospital for Special Surgery Research Institute and Weill Cornell College of Medicine, New York, NY

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MKMimi Y Kim
Mimi Y Kim
MGMarta M Guerra
Marta M Guerra
EKElianna Kaplowitz
Elianna Kaplowitz
CLCarl A Laskin
Carl A Laskin
MPMichelle Petri
Michelle Petri
JSJane E Salmon
Jane E Salmon
Objective Studies in mouse models implicate complement activation as a causative factor in adverse pregnancy outcomes (APOs). We investigated whether activation of complement early in pregnancy predicts APOs in women with systemic lupus erythematosus (SLE) and/or antiphospholipid (aPL) antibodies. Methods The PROMISSE Study enrolled pregnant women with SLE and/or aPL antibodies (n=487) and pregnant healthy controls (n=204) at <12 weeks gestation and evaluated them monthly. APOs were: fetal/neonatal death, preterm delivery <36 weeks because of placental insufficiency or preeclampsia and/or growth restriction <5th percentile. Complement activation products were measured on serial blood samples obtained at each monthly visit. Results APO occurred in 20.5% of SLE and/or aPL pregnancies. As early as 12–15 weeks, levels of Bb and sC5b-9 were significantly higher in patients with APOs and remained elevated through 31 weeks compared with those with normal outcomes. Moreover, Bb and sC5b-9 were significantly higher in patients with SLE and/or aPL without APOs compared with healthy controls. In logistic regression analyses, Bb and sC5b-9 at 12–15 weeks remained significantly associated with APO (ORadj=1.41 per SD increase; 95% CI 1.06 to 1.89; P=0.019 and ORadj=1.37 per SD increase; 95% CI 1.05 to 1.80; P=0.022, respectively) after controlling for demographic and clinical risk factors for APOs in PROMISSE. When analyses were restricted to patients with aPL (n=161), associations between Bb at 12–15 weeks and APOs became stronger (ORadj=2.01 per SD increase; 95% CI 1.16 to 3.49; P=0.013). Conclusion In pregnant patients with SLE and/or aPL, increased Bb and sC5b-9 detectable early in pregnancy are strongly predictive of APOs and support activation of complement, particularly the alternative pathway, as a contributor to APOs.

8 April 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SHSeunghee Hong
Seunghee Hong
RBRomain Banchereau
Romain Banchereau
BMBat-Sheva L. Maslow
Bat-Sheva L. Maslow
MGMarta M. Guerra
Marta M. Guerra
JCJacob Cardenas
Jacob Cardenas
VPVirginia Pascual
Virginia Pascual
Systemic lupus erythematosus carries an increased risk of pregnancy complications, including preeclampsia and fetal adverse outcomes. To identify the underlying molecular mechanisms, we longitudinally profiled the blood transcriptome of 92 lupus patients and 43 healthy women during pregnancy and postpartum and performed multicolor flow cytometry in a subset of them. We also profiled 25 healthy women undergoing assisted reproductive technology to monitor transcriptional changes around embryo implantation. Sustained down-regulation of multiple immune signatures, including interferon and plasma cells, was observed during healthy pregnancy. These changes appeared early after embryo implantation and were mirrored in uncomplicated lupus pregnancies. Patients with preeclampsia displayed early up-regulation of neutrophil signatures that correlated with expansion of immature neutrophils. Lupus pregnancies with fetal complications carried the highest interferon and plasma cell signatures as well as activated CD4+ T cell counts. Thus, blood immunomonitoring reveals that both healthy and uncomplicated lupus pregnancies exhibit early and sustained transcriptional modulation of lupus-related signatures, and a lack thereof associates with adverse outcomes. Graphical Abstract

10 April 2025 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
DBD. Ware Branch
D. Ware Branch
MKMimi Y. Kim
Mimi Y. Kim
MGMarta M. Guerra
Marta M. Guerra
JWJoseph Worden
Joseph Worden
CLCarl A. Laskin
Carl A. Laskin
JSJane E Salmon
Jane E Salmon

24 October 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
CYCécile M Yelnik
Cécile M Yelnik
XXXianhong Xie
Xianhong Xie
MGMarta M Guerra
Marta M Guerra
NCNathalie Costedoat-Chalumeau
Nathalie Costedoat-Chalumeau
AKArezou Khosroshahi
Arezou Khosroshahi
JSJane E Salmon
Jane E Salmon

9 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NMNaomi I Maria
Naomi I Maria
YXYunwei Xia
Yunwei Xia
CRChirag Raparia
Chirag Raparia
KLKe Lin
Ke Lin
SMShani Martinez
Shani Martinez
ADAnne Davidson
Anne Davidson
Anti-phospholipid (APL) autoantibodies confer a high risk for adverse pregnancy outcomes, especially in Systemic Lupus Erythematosus (SLE). While human TLR8 (huTLR8) has been implicated in APL antibody-mediated placental injury in vitro , its in vivo role in pregnancy is unexplored. We report a novel mouse model of pregnancy loss in SLE-prone mice expressing huTLR8. Placental analysis revealed early developmental defects starting post-implantation, including a thin junctional zone, impaired vascularization, infarcts, and inflammation. Profound immune dysregulation was evident at E8.5 including increased myeloid cells and CD8 T cells and decreased uterine natural killer (uNK) cells. RNA sequencing revealed downregulated pregnancy-specific glycoproteins, reduced uNK cell-associated genes, and an upregulated myeloid cell signature. Bone marrow chimera studies demonstrated preferential activation of huTLR8-expressing placental Ly6C + monocytes. Spatial transcriptomics at E9.5 confirmed uNK cell loss, decreased IL15 expression by both stromal and myeloid cells, and discrete inflammatory aggregates in the maternal layers containing myeloid cells and IFNγ-expressing CD8 T cells. We propose that huTLR8, likely through myeloid cell activation and cytolytic T cell recruitment, drives placental injury in the context of SLE and APL autoantibodies. This model provides a valuable platform to dissect early pathogenic events in APL-associated pregnancy loss and identify new therapeutic targets.